Physician profile
Julia Brann
NPI 1366548133
$3,805.86
in general payments reported to CMS, 2019-2025
27 companies · $966 in 2025
The $966 reported for 2025 was more than what 80% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $429 · 2022: $850 · 2023: $841 · 2024: $719 · 2025: $966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,455 · Education: $71.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,455.08 |
| Education | $71.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $939.93 | 2021-2025 | |
| Alkermes, INC. | $395.46 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Indivior INC. | $293.24 | 2022-2025 | Sublocade, Perseris |
| Neurocrine Biosciences, INC. | $287.49 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $233.14 | 2021-2025 | Caplyta |
| Axsome Therapeutics, INC. | $207.00 | 2023-2025 | Sunosi, Auvelity |
| Teva Pharmaceuticals USA, INC. | $205.26 | 2022-2025 | Uzedy, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $193.15 | 2021-2023 | Trintellix |
| Sunovion Pharmaceuticals INC. | $172.30 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $155.26 | 2021-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $129.01 | 2022-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $78.85 | 2022-2023 | Invega Sustenna, Spravato, Invega Trinza |
| Lundbeck LLC | $61.04 | 2022-2024 | Brintellix, Rexulti |
| Neuronetics, INC. | $59.16 | 2024 | Neurostar Tms Therapy System |
| Acadia Pharmaceuticals INC | $54.98 | 2022-2023 | Nuplazid |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $43.92 | 2024 | |
| Idorsia Pharmaceuticals US INC | $43.13 | 2023 | Quviviq |
| Jazz Pharmaceuticals INC. | $42.96 | 2021-2025 | |
| Almatica Pharma LLC | $37.79 | 2022 | |
| Merck Sharp & Dohme LLC | $35.39 | 2022 | |
| Brainsway USA INC | $23.40 | 2024 | Brainsway Deep Tms System |
| Noven Therapeutics, LLC | $22.14 | 2021 | |
| Orexo US, INC. | $20.63 | 2024 | Zubsolv |
| E.R. Squibb & Sons, L.L.C. | $20.38 | 2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $19.06 | 2025 | |
| Corium, LLC | $17.68 | 2025 | Azstarys |
| Eisai INC. | $14.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Brann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.